Publikationen

1986, 1988, 1989, 1990, 1991, 1992, 1993, 1995, 1996,
1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005,
2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016

 

 

1986

  • Dannhardt, G.; Lehr, M.; Steindl, L.
    Antiphlogistic 2,3-dihydro-1H-pyrrolizines. Part 12. Carboxaldehyde and hydroxymethyl derivatives of 5,6-, 5,7- and 6,7-diaryl-2,3-dihydro-1H-pyrrolizines.
    Chem.-Ztg. 1986, 110, 267-271.

1988

  • Dannhardt, G.; Lehr, M.
    Antiinflammatory 2,3-dihydro-1H-pyrrolizines. XIII. Isomeric (diaryldihydropyrrolizinyl)acetic acids and 2-(diaryldihydropyrrolizinyl)ethanols.
    Arch. Pharm. 1988, 321, 159-162.
  • Dannhardt, G.; Lehr, M.
    Antiinflammatory 2,3-dihydro-1H-pyrrolizines. XIV. Isomeric diaryldihydropyrrolizinyl formic and -propionic acids.
    Arch. Pharm. 1988, 321, 545-549.
  • Dannhardt, G.; Laufer, S.; Lehr, M.
    HPLC determination of etofenamate and flufenamic acid in biological materials.
    Clin. Chem. 1988, 34, 2580.

1989

  • Dannhardt, G.; Debaerdemaeker, T.; Lehr, M.
    Antiphlogistic 2,3-dihydro-1H-pyrrolizines. 15. Crystal structure of diphenyldihydropyrrolizine regioisomers.
    Chem.-Ztg 1989, 113, 249-252.

1990

  • Dannhardt, G.; Lehr, M.
    Antiphlogistic 2,3-dihydro-1H-pyrrolizines. 16. Studies on the reaction of isomeric diaryldihydropyrrolizines with 2,2-dimethyl-1,3-dioxan-4,6-dione (Meldrum´s acid).
    Chem.-Ztg 1990, 114, 244-246.
  • Dannhardt, G.; Steindl, L.; Lehr, M.
    Preparation of pyrroles and pyrrolizines as lipoxygenase and cyclooxygenase inhibitors.
    EP 397175 1990 (Chem. Abstr. 1991, 114: P163999a).

1991

  • Dannhardt, G.; Lehr, M.; Mayer, K.K.; Steindl, L.
    Volatile alkaloids of the caryopses of Lolium temulentum: genuine compounds and artifacts.
    Pharm. Pharmacol. Lett. 1991, 1, 7-10.
  • Lehr, M.; Schmid, W. 
    Simple and specific HPLC procedure for the determination of cyclamate in fruit beverages after conversion to N,N-dichlorocyclohexylamine.
    Z. Lebensm. Unters. Forsch.  1991, 192, 335-338.  

1992

  • Dannhardt, G.; Lehr, M.
    In vitro evaluation of 5-lipoxygenase and cyclooxygenase inhibitors using bovine neutrophils and platelets and HPLC.
    J. Pharm. Pharmacol. 1992, 44, 419-424.
  • Lehr, M.
    In vitro assay for the evaluation of phospholipase A2 inhibitors using bovine platelets and HPLC with UV-detection.
    Pharm. Pharmacol. Lett. 1992, 2, 176-179.

1993

  • Dannhardt, G.; Lehr, M.
    Nonsteroidal antiinflammatory agents, XVII: Inhibition of bovine cyclooxygenase and 5-lipoxygenase by N-alkyldiphenylpyrrolyl acetic and propionic acid derivatives.
    Arch. Pharm. 1993, 326, 157-162.
  • Lehr, M.; Schmid, W. 
    Solid-phase extraction in the determination of sweeteners in foods by HPLC.    
    Deutsche Lebensmittel-Rundschau 1993, 89, 43-45.

1995

  • Lehr, M.
    In vitro assay for the evaluation of inhibitors of 85 kDa cytosolic phospholipase A2 by measuring phorbol ester-induced arachidonic acid release from bovine platelets with HPLC/UV-detection.
    Pharm. Pharmacol. Lett. 1995, 5, 108-111.
  • Lehr, M.
    Preparation of acylpyrrolylalkanoates and related compounds as inhibitors of phospholipase A2.
    DE 4325204 1995 (Chem. Abstr. 1995, 122: P187385g).
  • Lehr, M.
    Acylpyrrole-alkanoic acids and indole-2-alkanoic acids plus their derivatives for use as inhibitors of phospholipase A2.
    PCT WO95/13266 1995 (Chem. Abstr. 1995, 123: P32958f).

1996

  • Lehr, M.
    3-(Octadecanoylaminomethyl)indole-2-carboxylic acid derivatives and 1-methyl-3-octadecanoyl-indole-2-carboxylic acid as inhibitors of cytosolic phospholipase A2.
    Arch. Pharm. Pharm. Med. Chem. 1996, 329, 386-392.
  • Lehr, M.
    3-(3,5-Dimethyl-4-octadecanoylpyrrol-2-yl)propionic acids as inhibitors of 85 kDa cytosolic phospholipase A2.
    Arch. Pharm. Pharm. Med. Chem. 1996, 329, 483-488.

1997

  • Lehr, M.
    Synthesis, biological evaluation, and structure-activity relationships of 3-acylindole-2- carboxylic acids as inhibitors of the cytosolic phospholipase A2.
    J. Med. Chem. 1997, 40, 2694-2705.
  • Lehr, M.
    Structure-activity relationship studies on (4-acylpyrrol-2-yl)alkanoic acids as inhibitors of the cytosolic phospholipase A2: Variation of the alkanoic acid substituent, the acyl chain and the position of the pyrrole nitrogen.
    Eur. J. Med.Chem. 1997, 32, 805-814.
  • Lehr, M.
    Structure-activity relationships of (4-acylpyrrol-2-yl)alkanoic acids as inhibitors of the cytosolic phospholipase A2: Variation of the substituents in position 1, 3, and 5.
    J. Med. Chem. 1997, 40, 3381-3392.

1998

  • Lehr, M.
    Preparation of acylpyrrole- and acylindoledicarboxylic acids as phospholipase A2 inhibitors.
    PCT WO98/05637 1998 (Chem. Abstr. 1998, 128: 167350n).
  • Lehr, M.
    Preparation of 3-acylpyrole- and indole-2-carboxylic acids as inhibiting agents of cytosolic phospholipase A2.
    DE 19638408 1998 (Chem. Abstr. 1998, 128: 257331m).

1999

  • Lehr, M.; Griessbach, K.
    Cell lytic and cPLA2-inhibitory properties in bovine platelets of the commercially available cPLA2 inhibitors, arachidonyltrifluoromethyl ketone, methyl arachidonylfluoro-phosphonate and palmityltrifluoromethyl ketone.
    Pharm. Pharmacol. Commun. 1999, 5, 389-393.
  • Weichel, O.; Hilgert, M.; Chatterjee, S.S.; Lehr, M.; Klein, J.
    Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus.
    Naunyn-Schmiedeberg´s Arch. Pharmacol. 1999, 360, 609-615.

2000

  • Lehr, M.; Griessbach K.
    Involvement of different protein kinases and phospholipases A2 in phorbol ester (TPA)-induced arachidonic acid liberation in bovine platelets.
    Mediat. Inflamm. 2000, 9, 31-34.
  • Lehr, M.
    Cytosolic phospholipase A2 as a target for drug design.
    Drugs Fut. 2000, 25, 823-832.
  • Lehr, M.; Schulze Elfringhoff, A.
    Comparison of the inhibition of the cytosolic phospholipase A2-mediated arachidonic acid release by several indole-2-carboxylic acids and 3-(pyrrol-2-yl)propionic acids in bovine and in human platelets.
    Arch. Pharm. Pharm. Med. Chem. 2000, 333, 312-314.

2001

  • Lehr, M.
    Phospholipase A2 inhibitors in inflammation.
    Expert Opin. Ther. Patents 2001, 11, 1123-1136.
  • Lehr, M.; Klimt, M.; Schulze Elfringhoff A.
    Novel 3-dodecanoylindole-2-carboxylic acid inhibitors of cytosolic phospholipase A2.
    Bioorg. Med. Chem. Lett. 2001, 11, 2569-2572.

2002

  • Risse, D.; Schulze Elfringhoff, A.; Lehr, M.
    Determination of the cell lytic properties of amphiphilic inhibitors of the cytosolic phospholipase A2 against human platelets by measuring the liberation of serotonin with high-performance liquid chromatography and fluorescence detection.
    J. Chromatogr. B 2002, 769, 185-190.
  • Albers, C.; Lehr, M.; Beike, J.; Köhler, H.; Brinkmann, B.
    Synthesis of a psilocin hapten and a protein-hapten conjugate.
    J. Pharm. Pharmacol. 2002, 54, 1265-1270.
  • Griessbach, K.; Klimt, M.; Schulze Elfringhoff, A.; Lehr, M.
    Structure-activity relationship studies of 1-substituted 3-dodecanoylindole-2-carboxylic acids as inhibitors of the cytosolic phospholipase A2-mediated arachidonic acid release in intact platelets.
    Arch. Pharm. Pharm. Med. Chem. 2002, 335, 547-555.

2003

  • Schmitt, M.; Lehr M.
    High-performance liquid chromatographic assay with ultraviolet spectrometric detection for the evaluation of inhibitors of secretory phospholipase A2.
    J. Chromatogr. B 2003, 783, 327-333.

2004

  • Ludwig, J.; Lehr, M.
    Convenient Synthesis of Pyrrole- and Indolecarboxylic Acid tert-Butylesters.
    Synthetic Commun. 2004, 34, 3691-3695.
  • Lehr, M.; Ludwig, J.
    Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase A2.
    PCT WO04/069797 2004.
  • Albers, C.; Köhler, H.; Lehr, M.; Brinkmann, B.; Beike, J.
    Development of a psilocin immunoassay for serum and blood samples.
    Int. J. Legal Med. 2004, 118, 326-331.
  • Schmitt, M.; Lehr, M.
    HPLC assay with UV spectrometric detection for the evaluation of inhibitors of cytosolic phospholipase A2.
    J. Pharm. Biomed. Anal. 2004, 35, 135-142.

2005

  • Ghasemi, A.; Schulze Elfringhoff, A.; Lehr, M.
    Structure-activity relationship studies of 3-dodecanoylindole-2-carboxylic acid inhibitors of cytosolic phospholipase A2α-mediated arachidonic acid release in intact platelets: variation of the keto moiety.
    J. Enzyme Inhib. Med. Chem. 2005, 20, 429-437.

2006

  • Ludwig, J.; Bovens, S.; Brauch, C.; Schulze Elfringhoff, A.; Lehr, M.
    Design and synthesis of 1-indole-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A2α.
    J. Med. Chem. 2006, 49, 2611-2620.
  • Lehr, M.
    Inhibitors of phospholipase A2α as potential anti-inflammatory drugs.
    Anti-Inflammatory Anti-Allergy Agents Med. Chem. 2006, 5, 149-161.
  • Fritsche, A.; Deguara, H.; Lehr, M.
    Convenient synthesis of tert-butyl esters of indole-5-carboxylic acid and related heterocyclic carboxylic acids.
    Synth. Commun. 2006, 36, 3117-3123.
  • Frommherz, L.; Kintz, P.; Kijewski, H.; Köhler, H.; Lehr, M.; Brinkmann, B.; Beike, J.
    Quantitative determination of taxine B in body fluids by LC-MS-MS.
    Int. J. Legal. Med. 2006, 120, 346-351.

2007

  • Fabian, J.; Lehr, M.
    Normal-phase HPLC and HPLC-MS studies of the metabolism of a cytosolic phospholipase A2α inhibitor with activated ketone group by rat liver microsomes.
    J. Pharm. Biomed. Anal. 2007, 43, 601-605.
  • Hess, M.; Schulze Elfringhoff, A.; Lehr, M.
    1-(5-Carboxy- and 5-carbamoylindol-1-yl)propan-2-ones as inhibitors of human cytosolic phospholipase A2α: bioisosteric replacement of the carboxylic acid and carboxamide moiety.
    Bioorg. Med. Chem. 2007, 15, 2883-2891.

2008

  • Frommherz, L. ;Köhler, H.; Brinkmann, B.; Lehr, M.; Beike, J.
    LC-MS assay for quantitative determination of cardio glycoside in human blood
    Int. J. Legal. Med. 2008, 122, 109-114.
  • Schmolke, M., Fabian, J.; Lehr, M.
    High-performance liquid chromatographic assay with ultra-violet spectrometric detection for the evaluation of inhibitors of phosphatidylinositol-specific phospholipase C.
    Anal. Biochem. 2008, 375, 291-298.
  • Fritsche, A., Schulze Elfringhoff, A.; Fabian, J.; Lehr, M.
    1-(2-Carboxyindol-5-yloxy)propan-2-ones as inhibitors of human cytosolic phospholipase A2α: synthesis, biological activity, metabolic stability and solubilty.
    Bioorg. Med. Chem. 2008, 16, 3489-3500.
  • Hess, M.; Schulze Elfringhoff, A.; Lehr, M.
    Design and synthesis of 3-pyrrol-3-yl-3H-isobenzofuran-1-ones as inhibitors of human cytosolic phospholipase A2α.
    J. Enzyme Inhib. Med. Chem. 2008, 23, 946-957.

2009

  • Bovens, S.; Kaptur, M.; Schulze Elfringhoff, A.; Lehr, M.
    1-(5-Carboxyindol-1-yl)propan-2-ones as inhibitors of human cytosolic phospholipase A2α: synthesis and properties of bioisosteric benzimidazole, benzotriazole and indazole analogues.
    Bioorg. Med. Chem. Lett. 2009, 19, 2107-2111.
  • Forster, L.; Schulze Elfringhoff, A.; Lehr, M.
    High performance liquid chromatographic assay with fluorescence detection for the evaluation of inhibitors against fatty acid amide hydrolase.
    Anal. Bioanal. Chem. 2009, 394, 1679-1685.
  • Lehr, M.; Bovens, S.
    Novel heteroaryl-substituted acetone derivates, suitable for inhibiting phospholipase A2.
    PCT WO2009/040314, 2009.

2010

  • Forster, L.; Ludwig, J.; Kaptur, M.; Bovens, S.; Schulze Elfringhoff, A.; Holtfrerich, A.; Lehr, M.
    1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A2α and fatty acid amide hydrolase.
    Bioorg. Med. Chem. 2010, 18, 945-952.
  • Holtfrerich, A.; Makharadze, T.; Lehr, M.
    High-performance liquid chromatography assay with fluorescence detection for the evaluation of inhibitors against human recombinant monoacylglycerol lipase.
    Anal. Biochem. 2010, 399, 218-224.
  • Drews, A.; Bovens, S.; Roebrock, K.; Sunderkötter, C.; Reinhardt, D.; Schäfers, M.; van der Velde, A,; Schulze Elfringhoff, A.; Fabian, J.; Lehr, M.
    1-(5-Carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A2α with reduced lipophilicity: synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical in vivo activity.
    J. Med. Chem. 2010, 53, 5165-5178.
  • Ghomashchi, F.; Naika, G.S.; Bollinger, J.G.; Aloulou, A.; Lehr, M.; Leslie, C.C.; Gelb, M.H.
    Interfacial kinetic and binding properties of mammalian group IVB phospholipase A2 (cPL A2beta) and comparison to the other cPLA2 isoforms.
    J. Biol. Chem. 2010, 285, 36100-36111.
  • Bovens, S.; Schulze Elfringhoff, A.; Kaptur, M.; Reinhardt, D.; Schäfers, M.; Lehr, M.
    1-(5-Carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A2α: effect of substituents in position 3 of the indole scaffold on inhibitory potency, metabolic stability, solubility, and bioavailability.
    J. Med. Chem. 2010, 53, 8298-8308.

2011

  • Zahov, S.; Drews, A.; Hess, M.; Schulze Elfringhoff, A.; Lehr, M. 1-(3-Biaryloxy-2-oxopropyl)indol-5-carboxylic acids and related compunds as dual ihnibitors of human cytosolic phospholipase A2α and fatty acid amide hydrolase.
    ChemMedChem 2011, 6, 544-549.
  • Kaptur, M.; Schulze Elfringhoff, A.; Lehr, M.; Structure–activity relationship studies on 1-(5-carboxyindol-1-yl)-propan-2-one inhibitors of human cytosolic phospholipase A2α: variation of the activated ketone moiety.
    Bioorg. Med. Chem. Lett. 2011, 21, 1773-1776.

2012

  • Rusch, M.; Zahov, S.; Vetter, I. R.; Lehr, M.; Hedberg, C. Design, synthesis and evaluation of polar head group containing 2-keto-oxazole inhibitors of fatty acid amide hydrolase (FAAH).
    Bioog. Med. Chem. 2012, 20, 1100 - 1112.
  • Wiegard, A.; Hanekamp, W.; Griessbach, K.; Fabian, J.; Lehr, M. Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E(2) synthase-1.
    Eur. J. Med. Chem. 2012, 48, 153 - 163.
  • Roebrock, K.; Wolf, M.; Bovens, S.; Lehr, M.; Sunderkötter, C. Inhibition of benzalkonium chloride-induce skin inflammation in mice by an indol-1-ylpropan-2-one inhibitor of cytosolic phospholipase A2α.
    Br. J. Dermatol. 2012, 166, 306 - 316.
  • Hanekamp, W.; Lehr, M. Determination of arachidonic acid by on-line solid-phase extraction HPLC with UV detection for screening of cytosolic phospholipase A2α inhibitors.
    J. Chromatogr. B 2012, 900, 79 - 84.
  • Lehr, M. Inhibitors of cytosolic phospholipase A2α as anti-inflammatory drugs.
    Anti-Inflammatory Drug DiscoveryLevin, J. I., Laufer, S., Thurston, D. E., Eds.; 2012; pp.35 - 57.

2013

  • Rempel, V.; Fuchs, A.; Hinz, S.; Karcz, T.; Lehr, M.; Koetter, U.; Müller, C. E.
    Magnolia extract, magnolol and metabolites: activation of cannabinoid CB2 receptors and blockade of the related GPR55.
    ACS Med. Chem. Lett. 2013, 4, 41-45.
  • Holtfrerich, A.; Hanekamp, W.; Lehr, M.
    (4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)
    Eur. J. Med. Chem. 2013, 63, 64-75
  • Fabian, J.; Hanekamp, W.; Thomas, M. H.; Olivier, J. L.; Lehr, M.
    Investigations on the metabolic stability of cytosolic phospholipase A2α inhibitors with 1-indolylpropan-2-one structure.
    Chem. Biol. Interact. 2013, 206, 356-363.

2014

  • Martin, R.; Schürenkamp, J.; Pfeiffer, H.; Lehr, M.; Köhler, H.
    Synthesis, hydrolysis and stability of psilocin glucuronide.
    Forensic Sci. Int. 2014, 237, 1-6.
  • Sundermann, T.; Lehr, M.
    Synthesis of 1-tetrazolylalkan-2-amines and -carbamates.
    Synth. Commun. 2014, 2014, 44,1641-1648.
  • Sundermann, T.; Arnsmann, M.; Schwarzkopf, J.; Hanekamp, W.; Lehr, M.
    Convergent and enantioselective syntheses of cytosolic phospholipase A2α inhibiting N-(1-indazol-1-ylpropan-2-yl)carbamates.
    Org. Biomol. Chem. 2014, 12, 4021-4030
  • Terwerge, T.; Dahlhaus, H.; Hanekamp, W.; Lehr, M.
    omega-Heteroarylalkylcarbamates as inhibitors of fatty acid amide hydrolase (FAAH).
    Med. Chem. Commun. 2014, 5, 932-936.
  • Schwarzkopf, J.; Sundermann, T.; Arnsmann, M.; Hanekamp, W.; Fabian, J.; Heidemann, J.; Pott, A. F.; Bettenworth, D.; Lehr, M.
    Inhibitors of cytosolic phospholipase A2α with carbamate structure: synthesis, biological activity, metabolic stability, and bioavailability.
    Med. Chem. Res. 2014, 23, 5250-5262
  • Lehr, M.; Arnsmann M.
    Preparation of substituted heteroaryl acetone derivatives useful in the treatment of inflammations and cancer.
    DE102012017516 2014.
  • Lehr, M.; Terwege, T.
    Preparation of aryl-N-(arylalkyl)carbamates as inhibitors of fatty acid amide hydrolase.
    DE102012018115 2014.
  • Lehr, M.; Arnsmann, M.; Schwarzkopf, J.
    Preparation of N-isopropylcarbamates useful in the treatment of inflammation and cancer.
    DE102012018789 2014.

2015

  • Sundermann, T.; Fabian, J.; Hanekamp, W.; Lehr, M.
    1-Heteroaryl-3-phenoxypropan-2-ones as inhibitors of cytosolic phospholipase A2a and fatty acid amide hydrolase: Effect of the replacement of the ether oxygen with sulfur and nitrogen moieties on enzyme inhibition and metabolic stability
    Bioorg. Med. Chem. 2015, 23, 2579-2592
  • Lehr, M.; Fabian, J.; Hanekamp, W.
    Involvement of microsomal NADPH-cytochrome P450 reductase in metabolic reduction of drug ketones.
    Biopharm. Drug Dispos. 2015, 36, 398-404.

2016

  • Sundermann, T.; Hanekamp, W.; Lehr, M.
    Structure-activity relationship studies on 1-heteroaryl-3-phenoxypropan-2-ones acting as inhibitors of cyto­solic phos­pho­lipase A2a and fatty acid amide hydro­lase: replacement of the activated ketone group by other serine traps.
    J. Enzyme Inhib. Med. Chem. 2016, 31, 653-663.
  • Althaus, J.; Hake, T.; Hanekamp, W.; Lehr, M.
    1-(5-Carboxyindazol-1-yl)propan-2-ones as dual inhibitors of cyto­solic phospho­lipase A2a and fatty acid amide hydrolase: bioisosteric replacement of the carboxylic acid moiety.
    J. Enzyme Inhib. Med. Chem. 2016, 31 (Supp. 1), 131-140 accepted
  • Mergemeier, K.; Lehr, M.
    HPLC-UV method for evaluation of inhibitors of plasma amine oxidase using derivatization of an aliphatic aldehyde product with TRIS.
    Anal. Bioanal. Chem. 2016, 408, 4799-4807accepted
  • Terwege, T.; Hanekamp, W.; Garzinsky, D.; König, S.; Koch, O.; Lehr, M.
    Imidazolyl- and -tetrazolylalkylcarbamates as inhibitors of fatty acid amide hydrolase (FAAH): biological activity and in vitro metabolic stability.
    ChemMedChem 2016, 11, 429-443.

2017

  • Arnsmann, M.; Hanekamp, W.; Schulze Elfringhoff, A.; Lehr, M.
    Structure–activity relationship studies on 1-(2-oxopropyl)indole-5-carboxylic acids acting as inhibitors of cytosolic phospholipase A2: Effect of substituents at the indole 3-position on activity, solubility, and metabolic stability.
    Eur. J. Med. Chem. 2017, 125, 1107-1114.
  • Zahov, S.; Garzinsky, D.; Hanekamp, W.; Lehr, M.
    1-Heteroarylpropan-2-ones as inhibitors of fatty acid amide hydrolase: Studies on structure-activity relationships and metabolic stability.
    Bioorg. Med. Chem. 2017, 25, 825-837.
  • Sundermann, T. R.; Lehr, M.
    Enantioselective synthesis of fatty acid amide hydrola¬se inhibitors with 1,3-disubstituted butan-2-one scaffold.
    Tetrahedron: Asymmetry 2017, 28, 447-453.
  • Dahlhaus, H.; Hanekamp, W.; Lehr, M.
    (Indolylalkyl)piperidine carbamates as inhibitors of fatty acid amide hydrolase (FAAH).
    Med. Chem. Commun. 2017, 8, 616-620.

2018

  • Mergemeier, K.; Lehr, M.
    HPLC-UV assays for evaluation of inhibitors of mono and diamine oxidases using novel phenyltetrazolylalkanamine substrates.
    Anal. Biochem. 2018, 549, 29-38.
  • Garzinsky, D.; Zahov, S.; Ekodo Voundi, M.; Hanekamp, W.; Lehr, M.
    Tetrazolylpropan-2-ones as inhibitors of fatty acid amide hydrolase: Studies on structure-activity relationships and metabolic stability.
    Eur. J. Med. Chem. 2018, 160, 183-192.